NCT04583254View on ClinicalTrials.gov

Hypofractionated External-beam RadiOtherapy for Intact Cervical Cancer (HEROICC-Trial): A Feasibility Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

December 14, 2023

Study Completion Date

December 14, 2028

Conditions
Cervical Cancer
Interventions
RADIATION

External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Experimental

40 Gy / 15 Fractions EBRT + HDR-Brachytherapy

RADIATION

External beam radiotherapy (EBRT) + High-dose rate (HDR) Brachytherapy Standard of Care

45 Gy / 25 Fractions EBRT + HDR-Brachytherapy

DRUG

Concurrent Chemotherapy

Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles

Trial Locations (3)

V1Y 5L3

RECRUITING

BC Cancer - Kelowna, Kelowna

N6A 5W9

RECRUITING

London Health Sciences Centre - London Regional Cancer Program, London

M4N 3M5

RECRUITING

Odette Cancer Centre - Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

Academic Medical Organization of Southwestern Ontario

OTHER

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER